Literature DB >> 16132578

Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior.

Alexander D Borowsky1, Ruria Namba, Lawrence J T Young, Kent W Hunter, J Graeme Hodgson, Clifford G Tepper, Erik T McGoldrick, William J Muller, Robert D Cardiff, Jeffrey P Gregg.   

Abstract

Two cell lines, Met-1(fvb2) and DB-7(fvb2), with different metastatic potential, were derived from mammary carcinomas in FVB/N-Tg(MMTV-PyVmT) and FVB/N-Tg(MMTV-PyVmT ( Y315F/Y322F )) mice, transplanted into syngeneic FVB/N hosts and characterized. The lines maintain a stable morphological and biological phenotype after multiple rounds of in vitro culture and in vivo transplantation. The Met-1(fvb2) line derived from a FVB/N-Tg(MMTV-PyVmT) tumor exhibits invasive growth and 100% metastases when transplanted into the females FVB/N mammary fat pad. The DB-7(fvb2) line derived from the FVB/N-Tg(MMTV-PyVmT ( Y315F/Y322F )) with a "double base" modification at Y315F/Y322F exhibits more rapid growth when transplanted into the mammary fat pad, but a lower rate of metastasis (17%). The Met1(fvb2) cells show high activation of AKT, while DB-7(fvb2) cells show very low levels of AKT activation. The DNA content and gene expression levels of both cell lines are stable over multiple generations. Therefore, these two cell lines provide a stable, reproducible resource for the study of metastasis modulators, AKT molecular pathway interactions, and gene target and marker discovery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132578     DOI: 10.1007/s10585-005-2908-5

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  36 in total

Review 1.  Polyoma virus middle T antigen and its role in identifying cancer-related molecules.

Authors:  Stephen M Dilworth
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

2.  FISH probes for mouse chromosome identification.

Authors:  Y P Shi; G Mohapatra; J Miller; D Hanahan; E Lander; P Gold; D Pinkel; J Gray
Journal:  Genomics       Date:  1997-10-01       Impact factor: 5.736

3.  Transgenic Polyoma middle-T mice model premalignant mammary disease.

Authors:  J E Maglione; D Moghanaki; L J Young; C K Manner; L G Ellies; S O Joseph; B Nicholson; R D Cardiff; C L MacLeod
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

4.  Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.

Authors:  D H Lau; L Xue; L J Young; P A Burke; A T Cheung
Journal:  Cancer Biother Radiopharm       Date:  1999-02       Impact factor: 3.099

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.

Authors:  Gargi D Basu; Latha B Pathangey; Teresa L Tinder; Michelle Lagioia; Sandra J Gendler; Pinku Mukherjee
Journal:  Mol Cancer Res       Date:  2004-11       Impact factor: 5.852

7.  A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers.

Authors:  Diana Cozma; Luanne Lukes; Jessica Rouse; Ting Hu Qiu; Edison T Liu; Kent W Hunter
Journal:  Genome Res       Date:  2002-06       Impact factor: 9.043

8.  Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis.

Authors:  M A Webster; J N Hutchinson; M J Rauh; S K Muthuswamy; M Anton; C G Tortorice; R D Cardiff; F L Graham; J A Hassell; W J Muller
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

Review 9.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

10.  CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells.

Authors:  L Y Bourguignon; Z Gunja-Smith; N Iida; H B Zhu; L J Young; W J Muller; R D Cardiff
Journal:  J Cell Physiol       Date:  1998-07       Impact factor: 6.384

View more
  119 in total

1.  IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.

Authors:  Mike W Helms; Jennifer A Prescher; Yu-An Cao; Steven Schaffert; Christopher H Contag
Journal:  Cancer Immunol Immunother       Date:  2010-06-09       Impact factor: 6.968

2.  Modeling metastasis biology and therapy in real time in the mouse lung.

Authors:  Arnulfo Mendoza; Sung-Hyeok Hong; Tanasa Osborne; Mohammed A Khan; Kirk Campbell; Joseph Briggs; Ananth Eleswarapu; Lauren Buquo; Ling Ren; Stephen M Hewitt; El Habib Dakir; El-H Dakir; Susan Garfield; Renard Walker; Glenn Merlino; Jeffrey E Green; Kent W Hunter; Lalage M Wakefield; Chand Khanna
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

3.  p21CIP1 Promotes Mammary Cancer-Initiating Cells via Activation of Wnt/TCF1/CyclinD1 Signaling.

Authors:  Outhiriaradjou Benard; Xia Qian; Huizhi Liang; Zuen Ren; Kimita Suyama; Larry Norton; Rachel B Hazan
Journal:  Mol Cancer Res       Date:  2019-04-09       Impact factor: 5.852

4.  Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors.

Authors:  Katherine D Watson; Chun-Yen Lai; Shengping Qin; Dustin E Kruse; Yueh-Chen Lin; Jai Woong Seo; Robert D Cardiff; Lisa M Mahakian; Julie Beegle; Elizabeth S Ingham; Fitz-Roy Curry; Rolf K Reed; Katherine W Ferrara
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

Review 5.  Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography.

Authors:  Craig K Abbey; Alexander D Borowsky; Jeffery P Gregg; Robert D Cardiff; Simon R Cherry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-04       Impact factor: 2.673

6.  Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.

Authors:  Fernando Salvador; Alberto Martin; Celia López-Menéndez; Gema Moreno-Bueno; Vanesa Santos; Alberto Vázquez-Naharro; Patricia G Santamaria; Saleta Morales; Pierre R Dubus; Laura Muinelo-Romay; Rafael López-López; Jason C Tung; Valerie M Weaver; Francisco Portillo; Amparo Cano
Journal:  Cancer Res       Date:  2017-07-18       Impact factor: 12.701

7.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

8.  Tumor microenvironment regulates metastasis and metastasis genes of mouse MMTV-PymT mammary cancer cells in vivo.

Authors:  J L Werbeck; N K Thudi; C K Martin; C Premanandan; L Yu; M C Ostrowksi; T J Rosol
Journal:  Vet Pathol       Date:  2013-10-03       Impact factor: 2.221

Review 9.  Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer.

Authors:  Christina N Bennett; Jeffrey E Green
Journal:  Toxicol Pathol       Date:  2010-01-15       Impact factor: 1.902

10.  The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.

Authors:  Daniel P Hollern; Jordan Honeysett; Robert D Cardiff; Eran R Andrechek
Journal:  Mol Cell Biol       Date:  2014-06-16       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.